Eoneren/E+ via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary laggards, with the Health Care Select Sector SPDR Fund ( XLV ) down 5.29% in Q1 2026, slightly underperforming the S&P 500's 4.63% decline amid inflation pressures, rising Treasury yields, and tighter Medicare Advantage reimbursement conditions. The follow...
Eoneren/E+ via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary laggards, with the Health Care Select Sector SPDR Fund ( XLV ) down 5.29% in Q1 2026, slightly underperforming the S&P 500's 4.63% decline amid inflation pressures, rising Treasury yields, and tighter Medicare Advantage reimbursement conditions. The following list highlights mid-cap healthcare stocks that have earned the highest possible Seeking Alpha EPS Revision Grade of A+, spanning biotechnology, pharmaceuticals, health care services, and health care equipment. Below is a list of the top 10 mid-cap healthcare stocks with A-grade EPS revisions. The list includes companies from various healthcare sub-sectors including Biotechnology, Life Sciences Tools and Services, Health Care Equipment, Health Care Facilities, and Pharmaceuticals. The list is topped by ADMA Biologics, Inc. ( ADMA ), Adaptive Biotechnologies Corporation ( ADPT ), and LeMaitre Vascular, Inc. ( LMAT ), all holding the highest A+ EPS revision grade. Envista Holdings Corporation ( NVST ) and PACS Group, Inc. ( PACS ) round out the top five, with NVST earning a Strong Buy quant rating and PACS achieving the highest quant rating of the group at 4.95. Beyond the top five, the list includes Brookdale Senior Living Inc. ( BKD ) and Guardian Pharmacy Services, Inc. ( GRDN ) representing the senior care and pharmacy services segments. Integer Holdings Corporation ( ITGR ) and Phibro Animal Health Corporation ( PAHC ) also made the list with solid A grades, while Alignment Healthcare, Inc. ( ALHC ) closes out the top 10 with an A- EPS revision grade. Here is the list: ADMA Biologics, Inc. ( ADMA ), EPS revision: A+ Adaptive Biotechnologies Corporation ( ADPT ), EPS revision: A+ LeMaitre Vascular, Inc. ( LMAT ), EPS revision: A+ Envista Holdings Corporation ( NVST ), EPS revision: A+ PACS Group, Inc. ( PACS ), EPS revision: A+ Brookdale Senior Living Inc. ( BKD ), EPS...
Svetlana123/iStock via Getty Images I have a couple of regrets in my life, but only a few rival the anguish I've felt about the fact that I gave Richtech Robotics (NASDAQ: RR ) a hold rating when I covered it back in December . My conclusion at the time was that this was a speculative endeavor that isn't likely to work out, but that such is the nature of most “innovation co.”-style firms that blee...
Svetlana123/iStock via Getty Images I have a couple of regrets in my life, but only a few rival the anguish I've felt about the fact that I gave Richtech Robotics (NASDAQ: RR ) a hold rating when I covered it back in December . My conclusion at the time was that this was a speculative endeavor that isn't likely to work out, but that such is the nature of most “innovation co.”-style firms that bleed money on cutting-edge tech. My conclusion of “maybe moonshot” was reasonable for the information I had found at the time. I've learned some things since then that changed my mind dramatically, and I'm downgrading the stock as much as possible. Truthfully, this isn't me delivering breaking news; the market figured a lot of this out before me. Here's the scorecard so you can see how bad it's been for them since I wrote the hold article in December: Seeking Alpha Spending More, Making Less RR is a robotics manufacturer based in Las Vegas, NV, that produces several models of robots. They are designed to perform tasks normally assigned to low-skill workers, like in warehousing, serving, and very basic manufacturing (demos show the robots putting screws into metal cases). These are not a profitable offering in our current market; the company consistently loses money, with its last quarterly loss its highest on record, at ($8.41M). Data by YCharts I always want to give these kinds of firms the benefit of the doubt, because I understand the “you have to spend money to make money” mantra, and so unprofitability isn't always a hard pass. But what are they spending on? Breaking down their spending, we see that their last quarterly spend on their cost of goods was $0.90M, their spending on research and development was at $0.34M, and their capital expenditures were at $0.07M. This looks like a lean operation when you remove the overhead. Overhead expenses cost Richtech $11.96M last quarter. The chart shows how truly divergent these costs are. Data by YCharts Okay, that's not a lot of ...
May Nymex natural gas (NGK26 ) on Friday closed down -0.022 (-0.82%). Nat-gas prices tumbled to a fresh 7.5-month nearest-futures low on Friday and settled lower. Forecasts for mild US spring weather that could potentially reduce nat-gas heating demand are weighing on prices. On Friday, the Commodity Weather Group said...
May Nymex natural gas (NGK26 ) on Friday closed down -0.022 (-0.82%). Nat-gas prices tumbled to a fresh 7.5-month nearest-futures low on Friday and settled lower. Forecasts for mild US spring weather that could potentially reduce nat-gas heating demand are weighing on prices. On Friday, the Commodity Weather Group said...
Tesla on Friday said Dutch regulators had approved the use of its driver assistance software which handles most driving tasks on highways and city streets under human supervision, the first regulatory sign‑off for the technology in Europe. "FSD Supervised has been approved in the Netherlands and will begin rolling out in the country shortly," Tesla said in a post on social media platform X. ...
Tesla on Friday said Dutch regulators had approved the use of its driver assistance software which handles most driving tasks on highways and city streets under human supervision, the first regulatory sign‑off for the technology in Europe. "FSD Supervised has been approved in the Netherlands and will begin rolling out in the country shortly," Tesla said in a post on social media platform X. "We're excited to bring FSD Supervised to more European countries soon." Wider adoption of FSD is central to Tesla's growth strategy.
TerraVest Industries ( TVK:CA ) announced on Friday that, in connection with its previously announced normal course issuer bid for up to 1,558,516 of its issued and outstanding common shares on the Toronto Stock Exchange, TerraVest has entered into an automatic share purchase plan with its designated broker to allow for purchases of shares. The share purchase plan will commence on April 15, 2026, ...
TerraVest Industries ( TVK:CA ) announced on Friday that, in connection with its previously announced normal course issuer bid for up to 1,558,516 of its issued and outstanding common shares on the Toronto Stock Exchange, TerraVest has entered into an automatic share purchase plan with its designated broker to allow for purchases of shares. The share purchase plan will commence on April 15, 2026, and end on or before August 21, 2026. Purchases under the Share Purchase Plan will be determined by TerraVest's broker in its sole discretion, without consultation with TerraVest, subject to the limitation of the Share Purchase Plan and the rules of the TSX. Source: Press Release More on TerraVest Industries Main Street exits KBK Industries after acquisition by TerraVest Historical earnings data for TerraVest Industries Dividend scorecard for TerraVest Industries Financial information for TerraVest Industries
Pelthos Therapeutics ( PTHS ) announced on Friday the appointment of John M. Gay as CFO, effective April 10, 2026, succeeding Francis Knuettel II. Gay brings over 25 years of public company finance and accounting experience, having served as the company's SVP, Finance & Accounting since 2025. He previously served as CFO of LNHC and in senior roles at Furiex Pharmaceuticals. More on Pelthos Therape...
Pelthos Therapeutics ( PTHS ) announced on Friday the appointment of John M. Gay as CFO, effective April 10, 2026, succeeding Francis Knuettel II. Gay brings over 25 years of public company finance and accounting experience, having served as the company's SVP, Finance & Accounting since 2025. He previously served as CFO of LNHC and in senior roles at Furiex Pharmaceuticals. More on Pelthos Therapeutics Pelthos Therapeutics Inc. (PTHS) Q4 2025 Earnings Call Transcript Pelthos signals continued ZELSUVMI momentum and targets expanded product launches through 2027 Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag Seeking Alpha’s Quant Rating on Pelthos Therapeutics Historical earnings data for Pelthos Therapeutics
PonyWang/iStock via Getty Images Introduction I wanted to take a look at another undercovered company on Seeking Alpha to see if there may be a hidden gem opportunity. The company in question is Radware Ltd. ( RDWR ). Since it just reported its full-year 2025 performance , there is no better time to delve deeper than now. The Company Radware provides protection for applications, APIs, and network ...
PonyWang/iStock via Getty Images Introduction I wanted to take a look at another undercovered company on Seeking Alpha to see if there may be a hidden gem opportunity. The company in question is Radware Ltd. ( RDWR ). Since it just reported its full-year 2025 performance , there is no better time to delve deeper than now. The Company Radware provides protection for applications, APIs, and network infrastructure, with the focus currently on cloud security through recurring revenue. As with many such companies, Radware is switching from product-like licensing to cloud services, subscriptions, and maintenance. The favorite metric the management likes to focus on, as well as analysts because of it, is annual recurring revenue, or ARR. Radware’s application helps protect against DDoS attacks, web application firewalls, bot management, and API security. For differentiation, the company leans into specialized application protection and DDoS defense rather than a broad security platform, with the use of machine-learning-based mitigation through behavioral baselines. Performance in 2025 Products grew at around 22% y/y to $189.6m, while services declined around 6% to $112.3m. Overall, total revenue grew close to 10% for the year. Seeking Alpha We can see that the growth engine for 2025 was the product segment. Why is that? The services revenue declined because Radware kept shifting toward subscription and cloud delivery and because the company saw double-digit growth in defense products . The decline in services isn’t worrying me. I don’t see it as a weakness, as it is just a mix shift toward higher-value recurring offerings, which I am confident will recover in the future. Taking a look at the company’s profitability, we can see something quite unusual. Gross margins are fantastic; however, essentially none of the gross profit trickles down into the income statement . It seems that the company spends particularly heavily on sales and marketing, as well as research and develo...
AI-focused cloud infrastructure provider CoreWeave (NASDAQ:CRWV), closed Friday at $102, up 10.87%. The stock moved higher after news of a multi-year AI cloud deal with Anthropic. It also announced an expanded capacity agreement with Meta Platforms (NASDAQ:META) this week. Invest
AI-focused cloud infrastructure provider CoreWeave (NASDAQ:CRWV), closed Friday at $102, up 10.87%. The stock moved higher after news of a multi-year AI cloud deal with Anthropic. It also announced an expanded capacity agreement with Meta Platforms (NASDAQ:META) this week. Invest
Blackstone Inc. filed for an initial public offering of a new data-center acquisition vehicle that plans to buy already-built and leased properties benefiting from the artificial intelligence boom. The new vehicle, Blackstone Digital Infrastructure Trust Inc., will target newly built data centers valued at between $250 million and $1.5 billion and leased to investment-grade hyperscalers, according...
Blackstone Inc. filed for an initial public offering of a new data-center acquisition vehicle that plans to buy already-built and leased properties benefiting from the artificial intelligence boom. The new vehicle, Blackstone Digital Infrastructure Trust Inc., will target newly built data centers valued at between $250 million and $1.5 billion and leased to investment-grade hyperscalers, according to its filing Friday with the US Securities and Exchange Commission. The properties are expected to yield 5.75% to 7% a year, or more, and the rent would automatically rise by 2% to 3% annually, the filing said. Blackstone plans to raise about $2 billion from the IPO, which could begin formal marketing later this month, Bloomberg reported earlier Friday. The firm has already approached sovereign wealth funds and other institutions for the first checks, aiming eventually to raise tens of billions of dollars from a broader group of investors. Read more: Blackstone Plans Public Company for AI Data-Center Buying Spree The move encapsulates two of the $1.3 trillion alternative-asset manager’s biggest initiatives: its bid to become the world’s largest investor in AI infrastructure and its push beyond pensions and endowments to reach individual investors. The offering also builds on Blackstone’s broader push into data centers. The firm’s roughly $25 billion bet on the sector has become one of its biggest plays on the artificial intelligence boom, underscoring how AI infrastructure requires vast amounts of land, power and capital. The vehicle, structured as a real estate investment trust, will be externally managed by a Blackstone-affiliated entity in return for base and incentive fees and will have priority over other Blackstone funds for data-center acquisitions sourced by the firm. Another affiliate is also expected to purchase shares in the IPO, according to the filing. The offering is being led by Goldman Sachs Group Inc., Citigroup Inc., Morgan Stanley, Barclays Plc, Bank of...
Quarter-final: Bath 43-41 Northampton Hosts recover from 21 points behind in first half There are big games and then there are pivotal contests which define entire campaigns. And when it came to the crunch it was Bath who just had enough power to make the semi-finals of the Champions Cup for the first time in 20 years thanks to a 76th minute try from Ted Hill. There is little to separate the two b...
Quarter-final: Bath 43-41 Northampton Hosts recover from 21 points behind in first half There are big games and then there are pivotal contests which define entire campaigns. And when it came to the crunch it was Bath who just had enough power to make the semi-finals of the Champions Cup for the first time in 20 years thanks to a 76th minute try from Ted Hill. There is little to separate the two best teams in England and here was another endlessly compelling battle of wits and wills. Plenty of work still has to be done to reach the final in Bilbao next month with Bath now set to face the winners of Sunday’s mouthwatering all-French tie between Bordeaux and Toulouse. This was a truly sensational hors d’oeuvre, though, with nine tries in the first half alone. Gone are the days of tiptoeing into knockout matches and hoping to edge it 9-6. Continue reading...
As the shot from Taty Castellanos rolled past José Sá and crawled towards the Wolves goal, West Ham’s bid for survival picked up pace. They looked doomed three months ago, but not any more. Nuno Espírito Santo’s side somehow found the motivation to go again after dropping seven points off 17th place in early January and if this escape act does end successfully they will certainly look back to the ...
As the shot from Taty Castellanos rolled past José Sá and crawled towards the Wolves goal, West Ham’s bid for survival picked up pace. They looked doomed three months ago, but not any more. Nuno Espírito Santo’s side somehow found the motivation to go again after dropping seven points off 17th place in early January and if this escape act does end successfully they will certainly look back to the impact made by their winter reinforcements. While Axel Disasi has brought order to a chaotic defence Castellanos and Pablo Felipe are starting to resemble a modern day John Hartson and Paul Kitson. An old-school kind of front two, they have altered the nature of West Ham’s attack with their running and link-up play. Pablo, only 22, is a workhorse and Castellanos, who looks quite the find from Lazio, got the two goals his running deserved in this crucial 4-0 win over Wolves. Continue reading...